Immunogenik, Inc.
Publicly observedGainesville, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Gainesville | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Immunogenik, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | XGX9CKVE5N68 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jul 2025Publicly observed
NIH SBIR/STTR award: Enhance Cancer Therapeutics with 3-in-1 CAR T Cells
USD 398,997.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant9 Jun 2025Publicly observed
NIH SBIR/STTR award: Advancing cancer therapy: Developing antibody blockade targeting a novel immune checkpoint, LAIR1/CD305
USD 398,997.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.